No Data
Bai Cheng Pharmaceutical (301096.SZ) released its 2024 performance, reporting a net loss attributable to shareholders of 52.7428 million yuan, turning from profit to loss.
Bai Cheng Pharmaceutical (301096.SZ) released its 2024 annual report, with a revenue of 8....
Baicheng Pharmaceutical: 2024 Annual Report Summary
Baicheng Pharmaceutical: 2024 Annual Report
Baicheng Pharmaceutical: Report for the first quarter of 2025
Bai Cheng Pharmaceutical (301096.SZ): A net loss of 26.1976 million yuan in the first quarter.
On April 22, Gelonghui reported that Baicheng Pharmaceutical (301096.SZ) announced its Q1 2025 report, with revenue of 0.129 billion yuan, a year-on-year decrease of 40.32%; net income attributable to shareholders of the listed company was -26.1976 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -36.1823 million yuan; EPS was -0.24 yuan.
Baicheng Pharmaceutical: 2024 Annual Results Forecast Revision Announcement